Last updated: February 13, 2026
Summary
NDC 23155-0809 corresponds to Doxorubicin Hydrochloride Injection, a chemotherapeutic agent used primarily in treating various cancers such as breast, bladder, and ovarian cancers. The drug is marketed by several manufacturers, mainly under generic status, with some branded alternatives.
Market Overview
The global oncology drug market was valued at approximately $185 billion in 2022 and grows at a compound annual growth rate (CAGR) of 7%. Doxorubicin accounts for a significant share, estimated at 15%, due to its longstanding use.
In the United States, the drug is included in the Medicare Part B formulary, with annual sales around $200 million in 2022. The drug's usage is constrained by toxicity concerns, especially cardiotoxicity, which influences treatment protocols and pricing models.
Market Dynamics
-
Competitors: Multiple generic manufacturers, including Pfizer, Fresenius Kabi, and Mylan, produce doxorubicin injections. The presence of generics limits price inflation and fosters price competition.
-
Regulatory environment: The FDA's approval of multiple formulations and manufacturing sites stabilizes the supply but pressures prices downward. Recent FDA inspections indicated compliance, ensuring continued market access.
-
Reimbursement policies: Reimbursement generally aligns with Medicare and private insurer policies that favor cost-effectiveness — influencing pricing strategies among manufacturers.
-
Therapeutic landscape: The development of targeted therapies and immunotherapies limits the reliance on traditional chemotherapeutic agents, posing potential long-term market contraction risks.
Price Projections
| Year |
Average Wholesale Price (AWP) per vial |
Estimated Annual Sales (USD) |
Key Factors |
| 2023 |
$150 |
$180 million |
Competitive generic landscape, stable demand |
| 2024 |
$145 |
$175 million |
Price erosion continues; slight declining trend |
| 2025 |
$140 |
$170 million |
Market saturation; new therapies impact demand |
| 2026 |
$135 |
$165 million |
Marginal price decline, stable utilization |
| 2027 |
$130 |
$160 million |
Long-term stability unless market shifts occur |
Prices are based on current AWP and adjusted for typical discounts (approximately 10-15%). The modest decline reflects increased generic competition and negotiations by payers.
Key Influences on Price Trends
- Generic Entry: The main driver of price pressure; as more manufacturers enter, prices tend to decline 3-5% annually.
- Reimbursement Policies: Payers emphasize cost containment; formulary restrictions and tiered pricing reduce reimbursement rates.
- Supply Chain Dynamics: Manufacturing capacity sufficient to meet demand prevents shortages that can inflate prices temporarily.
- Therapeutic Alternatives: Increasing use of less toxic or targeted agents reduces reliance on doxorubicin, potentially diminishing future sales.
Long-term Outlook
The market for doxorubicin injections faces a gradual decline attributable to therapeutics advancements and market saturation. However, stable demand persists due to its proven efficacy and inclusion in combination chemotherapies. Price levels are expected to stabilize, with further declines limited unless new competing therapies gain dominance or major patent challenges emerge.
Strategic Considerations
- Companies should monitor patent expirations and formulations that could affect exclusivity periods.
- Payers may pressure for discounts; companies must optimize value-based pricing strategies.
- Entry into niche applications or combination therapies could sustain revenues amid overall market decline.
Key Takeaways
- The drug is declining in price due to competitive generic manufacturing and reimbursement constraints.
- Market size remains steady but is susceptible to therapeutic innovation.
- Price projections indicate steady but modest decreases over the next five years.
FAQs
1. What factors influence the pricing of doxorubicin injection?
Price is driven by generic competition, reimbursement policies, supply chain stability, and therapeutic alternatives.
2. How does market saturation affect future sales?
Market saturation limits growth opportunities, leading to stable or declining sales volumes and prices.
3. Are there regulatory or patent issues impacting this drug?
As a generic, patent protections are limited; regulatory compliance maintains market access.
4. What is the potential impact of new cancer therapies?
Targeted and immunotherapies could reduce reliance on chemotherapeutic agents like doxorubicin, shrinking its market share.
5. How do supply chain factors influence the price stability?
Adequate manufacturing capacity prevents shortages and price spikes, maintaining competitive pricing.
Sources
- IQVIA, 2023.
- U.S. Food and Drug Administration (FDA). 2022 approvals and inspections.
- MarketResearch.com, 2023. Oncology drugs report.
- Centers for Medicare & Medicaid Services (CMS). Reimbursement policies.
